MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference.

The iShares U.S. Home Construction ETF presents a strong buying opportunity, as the housing market shows signs of recovery with improving supply and declining mortgage rates. Homebuilding companies have outperformed expectations, indicating robust growth potential for ITB, especially with anticipated rate cuts and economic recovery in the second half of the year. While ITB carries macroeconomic risks and higher volatility, it offers diversified exposure to the home construction industry, making it a compelling investment for those seeking growth.

International Game Technology's strategic shift to focus on its core lottery business, divesting digital operations, significantly reduces debt and enhances shareholder value. The company's lottery management model guarantees long-term contracts, providing stability and consistent cash flow, positioning it as a market leader. Despite a slight decline in overall sales, lottery revenues remain strong, with growth in iLottery and international markets, particularly Italy.

PAR Technology Corporation's transition to a subscription-based model and strategic acquisitions drive significant growth, with annual recurring revenue up 102% year-over-year. Key acquisitions like Delaget and TASK Group enhance PAR's capabilities in customer engagement, data analytics, and international expansion, broadening its market reach. Despite margin pressures and customer concentration risks, PAR's strong revenue growth and expanding partnerships, like with Burger King, support a positive long-term outlook.

In 2024's worst home sales since 1995, UWM smashed records with $96B in purchase loans while doubling its refinance market share to 12%. With a $3.5B profit precedent at 6%, UWM is primed for a $260B refinance origination surge if rates drop, capitalizing on future macroeconomic shifts. Despite a 92% Ishbia family-owned float fueling volatility and short-seller noise, UWM's $2.5B cash pile and committed dividend policy offers investors a great buying opportunity.

I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily.

Tesla's market share in Europe continued to shrink year-on-year in February, data showed on Tuesday, as sales of the all-electric car maker dropped for a second consecutive month despite rising overall EV registrations on the continent.

GENEVA--(BUSINESS WIRE)--Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities.

Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash of $2.30 per share, presenting a major buying opportunity despite past shareholder losses. Aggressive selling by Biotech Growth N.V. caused recent price volatility, but this creates a buying opportunity given BDTX's strong fundamentals.

Georges Elhedery, CEO of HSBC Holdings Plc, discusses the bank's restructuring initiative and its global strategy. Elhedery says HSBC has "great momentum" and expects to reallocate $1.5 billion in efficiencies into areas of growth and strength.

This is a big week for data concerning the consumer. PCE inflation price data is coming out Friday.

Meta shares have outperformed the S&P 500 since my Strong Buy recommendation on November 1, 2023, despite a recent pullback. The pullback presents a compelling buying opportunity, as Meta remains a highly attractive investment. Meta has potential to benefit from AI threats to Google's search business.

Lululemon's Q4 earnings are expected to be strong, but future growth may falter due to economic risks and increased competition, especially from Chinese brands. LULU's valuation is historically low, presenting a short-term dip-buying opportunity, but market saturation and shifting consumer preferences threaten long-term growth. High gross margins and brand loyalty are critical for Lululemon, but economic pressures and price-sensitive consumers may erode these advantages over time.

World Network WLD/USD was one of the cryptocurrency market's hottest coins Monday, amid speculation about a deal with Visa Inc . V to build a new stablecoin wallet.

Cognizant will offer solutions across key growth areas, including enterprise AI agents, tailored industry large language models and infrastructure with NVIDIA AI. TEANECK, N.J.

SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which also received FDA Fast Track for r/r SLE, extrarenal lupus, and lupus nephritis. However, UP421 might be the most promising. It restored insulin production in a type 1 diabetes patient.

Ellington Credit Company has shifted from a mortgage REIT to a closed-end fund focusing on high-yield CLOs, aiming for substantial gains. Despite potential high rewards, EARN's transition brings significant risks, with recent earnings volatility and a hefty debt load posing challenges. EARN's valuation appears attractive, trading at a discount with a low P/E ratio, suggesting potential upside if management successfully navigates the CLO market.

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) prior to November 2023 and continue to hold any of those NASDAQ: REGN shares, should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million in cash but faces a net loss, with a cash runway of approximately two years. The company's near-term success hinges on the results of the LOTIS-5 trial, crucial for confirming Zynlonta's efficacy and potential market expansion.

COLUMBUS, Ohio , March 24, 2025 /PRNewswire/ -- American Electric Power (Nasdaq: AEP) today announced the pricing of a registered underwritten offering of 19,607,844 shares of its common stock at a price to the public of $102.00 per share. Subject to certain conditions, all shares are expected to be borrowed by the forward counterparties (as defined below) (or their respective affiliates) from third parties and sold to the underwriters and offered in connection with the forward sale agreements described below.